Latest Cancer stem cell Stories
-- 2015/2016 clinical research strategy to be previewed SYDNEY, Jan.
This month a keynote address by Dr. James L. Sherley, Director of Boston’s Adult Stem Cell Technology Center, LLC, is featured on the website of the Omics Group.
SAN ANTONIO, December 11, 2014 /PRNewswire/ -- - The first study in the world combining Reparixin, an oral inhibitor of CXCR1/2, with standard
Shangqin Guo, Ph.D., a scientist at Yale University, is the recipient of the 2014 STEM CELLS’ Young Investigator Award.
Today, a new research report from Boston’s Adult Stem Cell Technology Center, LLC, published online in the Nature Publishing Group journal Cell Death and Disease, describes a new advance in
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
Research shows promise for increasing effectiveness of chemo and reduction of metastasis DALLAS, Nov.
On Thursday, October 30, at 4:10 pm at Rhode Island Hospital’s inaugural “Novel Stem Cells & Vesicles Symposium” in Providence, Dr. James L.
- An armed gangster.